Financial Performance - For the six months ended September 30, 2022, the group recorded total revenue of approximately HKD 28,400,000, an increase of about 7.72% compared to HKD 26,364,000 for the same period in 2021[4]. - The gross profit margin for the six months ended September 30, 2022, was approximately 81.74%, a decrease of about 0.77 percentage points from 82.51% in the same period of 2021[4]. - The group reported a loss attributable to owners of the company of approximately HKD 6,710,000 for the six months ended September 30, 2022, compared to a profit of HKD 7,206,000 in the same period of 2021, primarily due to the absence of a one-time gain from the sale of a subsidiary amounting to HKD 31,700,000[4]. - The total comprehensive loss for the period was HKD 2,829,000, compared to a total comprehensive income of HKD 24,148,000 for the same period in 2021[8]. - The company reported a basic loss per share of HKD 0.098 for the six months ended September 30, 2022, compared to earnings per share of HKD 0.566 for the same period in 2021[8]. - The group recorded a revenue of approximately HKD 28,400,000 for the six months ended September 30, 2022, representing an increase of about 7.72% compared to HKD 26,364,000 in the same period last year[50]. - The company reported a total comprehensive income of HKD 8,734,000 for the period, compared to HKD 13,638,000 in the previous year, reflecting a decline of 36.4%[13]. Assets and Liabilities - The total assets as of September 30, 2022, amounted to HKD 54,710,000, a decrease from HKD 60,448,000 as of March 31, 2022[10]. - The company's equity attributable to owners decreased to HKD 21,727,000 as of September 30, 2022, from HKD 29,591,000 as of March 31, 2022[10]. - Total liabilities increased to HKD 36,330,000 as of September 30, 2022, compared to HKD 34,081,000 as of March 31, 2022, reflecting a growth of 6.6%[11]. - Current liabilities rose to HKD 33,002,000 from HKD 29,228,000, marking an increase of 12.0%[11]. - The company’s total assets less current liabilities decreased to HKD 21,708,000 from HKD 31,220,000, a drop of 30.5%[11]. - Total equity and liabilities amounted to HKD 54,710,000 as of September 30, 2022, down from HKD 60,448,000 as of March 31, 2022, a decrease of 9.5%[11]. Cash Flow - The cash and cash equivalents as of September 30, 2022, were HKD 12,626,000, down from HKD 16,795,000 as of March 31, 2022[10]. - Cash and cash equivalents decreased to HKD 12,626,000 from HKD 26,362,000, representing a decline of 52.1%[20]. - Net cash used in operating activities was HKD (604,000) for the six months ended September 30, 2022, compared to HKD (11,580,000) for the same period in 2021, indicating an improvement[21]. - Net cash used in investing activities was HKD 159,000, a significant recovery from HKD (2,221,000) in the previous year[21]. - Net cash generated from financing activities was HKD (2,433,000), down from HKD 1,807,000 in the prior year, showing a decrease in financing inflow[21]. - The group’s cash flow from operations showed a significant negative shift, indicating potential liquidity challenges moving forward[21]. Employee Costs and Operations - The group incurred employee costs of HKD 5,804,000 for the three months ended September 30, 2022, compared to HKD 9,081,000 in 2021, a reduction of about 36.5%[34]. - Total employee costs for the six months ended September 30, 2022, amounted to approximately HKD 12,865,000, down from HKD 19,800,000 in the previous year[67]. - As of September 30, 2022, the group employed 103 full-time employees, a decrease from 137 employees as of March 31, 2022[67]. Dividends and Shareholder Information - The company did not recommend the distribution of dividends for the six months ended September 30, 2022, consistent with the previous year[4]. - The group did not recommend the payment of dividends for the six months ended September 30, 2022, consistent with the previous year[63]. - As of September 30, 2022, the major shareholder, Xingyang Global Limited, holds 1,581,959,460 shares, representing approximately 56.13% of the total issued shares[86]. - Ms. Zheng Huixian, as a spouse of the beneficial owner, holds 1,640,959,460 shares, accounting for about 58.22% of the total issued shares[86]. - New Hope International (Hong Kong) Limited owns 343,217,539 shares, which is approximately 12.18% of the total issued shares[86]. Corporate Governance - The company has adopted a code of conduct regarding securities trading by directors, which complies with GEM Listing Rules[98]. - The company has adhered to the corporate governance code as stipulated in the GEM Listing Rules during the six months ending September 30, 2022[99]. - The remuneration committee is responsible for determining the specific remuneration packages of all executive directors, considering factors such as comparable company salaries and performance-linked remuneration[100]. - The nomination and corporate governance committee was established to review the board's structure and recommend suitable candidates for board membership[102]. - The audit committee was established on November 2, 2001, consisting of three independent non-executive directors[103]. - The audit committee's main responsibilities include ensuring adequate financial controls and overseeing risk management and internal control systems[103]. - The unaudited consolidated performance for the review period has been reviewed by the audit committee and deemed compliant with applicable accounting standards and GEM listing rules[105]. Legal Matters - A lawsuit involving an indirect subsidiary resulted in a court ruling that required the subsidiary to refund approximately RMB 4,900,000 to the plaintiff and pay damages of about RMB 1,400,000[70][72]. Other Information - The group has not provided any significant impact on its financial position or performance due to the application of revised Hong Kong Financial Reporting Standards during the period[29]. - All revenues and assets of the group are primarily located in China, with no significant business or geographical segment reporting[33]. - The group completed the sale of its subsidiary on September 1, 2021, resulting in the exclusion of the subsidiary's financial performance from the consolidated financial statements[47]. - The group did not engage in any significant acquisitions or disposals of subsidiaries or associates during the review period[68]. - The group has not implemented any formal hedging or alternative policies to address foreign exchange risks, as most transactions are denominated in RMB and HKD[65]. - As of September 30, 2022, the group had pledged bank deposits of approximately zero HKD as collateral for general bank financing[66]. - The company did not purchase, sell, or redeem any of its listed securities during the six months ending September 30, 2022[94]. - There were no unexercised stock options under the stock option plan as of September 30, 2022, and no options were granted, exercised, canceled, or lapsed during the period[93]. - There were no significant events occurring after the reporting period[76]. - The company has changed its Hong Kong share transfer registration office address effective August 15, 2022[74]. - The company's board members have not reported any interests in share options or related securities as of September 30, 2022[84].
金威医疗(08143) - 2023 - 中期财报